News

Team (NYSE:TISI), a provider of inspection, mechanical, and heat-treating services to industrial sectors, reported results for Q2 2025 on August 12, 2025. The earnings report highlighted 8.5%

Generation Bio (NASDAQ:GBIO), a biotechnology firm developing cell-targeted siRNA therapeutics for autoimmune diseases, released its second quarter earnings on August 12, 2025. The main news was a

QuickLogic (NASDAQ:QUIK), a semiconductor company specializing in programmable logic chips and tools, reported earnings for Q2 FY2025 on August 12, 2025. The period brought disappointing financial

Iridex (NASDAQ:IRIX), a medical device company specializing in laser-based systems for eye disease treatments, reported its second quarter results on August 12, 2025, covering the three months ended

Webtoon Entertainment (NASDAQ:WBTN), a global digital comics publisher and platform operator, reported results on August 12, 2025. Revenue (GAAP) reached $348.3 million, coming in $7.7 million above

Vicarious Surgical (NYSE:RBOT), a developer focused on next-generation robotic technology for minimally invasive surgery, released its second quarter 2025 financial results on August 12, 2025. The

Armata Pharmaceuticals (NYSEMKT:ARMP), a clinical-stage biotech developing bacteriophage therapies for drug-resistant bacterial infections, released its second-quarter results on August 12, 2025

Hyliion (NYSEMKT:HYLN), an early-stage company developing clean power solutions for distributed generation, released its second quarter 2025 earnings on August 12, 2025. The company cut its 2025

Verrica Pharmaceuticals (NASDAQ:VRCA), a specialty dermatology company focused on skin disease treatments, released its earnings for the second quarter of fiscal 2025 on August 12, 2025. The

Pixelworks (NASDAQ:PXLW), a specialist in video display semiconductors and visual processing technology, reported its Q2 2025 results on August 12, 2025. The company posted GAAP revenue of $8.3

Luminar Technologies (NASDAQ:LAZR), a leading developer of laser-based sensors and software for advanced driver-assistance systems and autonomous vehicles, reported results for Q2 2025 on August 12

Erasca (NASDAQ:ERAS), a clinical-stage biotechnology company focused on developing cancer therapies targeting the RAS/MAPK pathway, released its second quarter results on August 12, 2025. The

Theravance Biopharma (NASDAQ:TBPH), a biopharmaceutical company focused on respiratory medicines and rare disease therapeutics, reported its Q2 2025 results on August 12, 2025. The company’s revenue

Absci (NASDAQ:ABSI), a biotechnology company focused on generative AI-driven drug discovery, issued its second quarter fiscal 2025 earnings on August 12, 2025. The release highlighted a steep

NeuroPace (NASDAQ:NPCE), a medical technology company known for its brain-responsive neuromodulation device for drug-resistant epilepsy, published its second quarter results on August 12, 2025

Pulse Biosciences (NASDAQ:PLSE), a medical device innovator focused on nanosecond pulsed field ablation (nsPFA) for treating various conditions, released its second-quarter 2025 results on August

Nexgel (NASDAQ:NXGL), a maker of hydrogel-based wound care and beauty products, released its second quarter results for fiscal 2025 on August 12, 2025. The key news from the release was strong

ProKidney (NASDAQ:PROK), a biopharmaceutical company developing cell therapies for chronic kidney disease (CKD), released its second quarter results on August 12, 2025. The main focus of the release

Zevra Therapeutics (NASDAQ:ZVRA), a biopharmaceutical company focused on rare diseases, announced its Q2 2025 financial results on August 12, 2025.

The most notable headline was a sharp

Fractyl Health (NASDAQ:GUTS), a clinical-stage biotech developing interventions for obesity and Type 2 Diabetes (T2D), reported its second quarter 2025 results on August 12, 2025. The period was

Lineage Cell Therapeutics (NYSEMKT:LCTX), a biotechnology company advancing cell-based therapies for serious diseases, released its earnings for the quarter ended June 30, 2025 on August 12, 2025

Citius Oncology (NASDAQ:CTOR), a biopharmaceutical company focused on cancer treatments, released results for its fiscal third quarter on August 12, 2025. The most pivotal news was an upside

Kopin (NASDAQ:KOPN), a technology firm specializing in microdisplays used in defense systems and industrial devices, reported Q2 FY2025 earnings on August 12, 2025. The company reported a sharp

Lululemon (NASDAQ: LULU) was once a market darling. It is now one of the worst-performing stocks of 2025. Shares are off close to 50% so far in 2025 on rising fears of competition and macroeconomic

This year has been an emotional roller coaster for shareholders of Nvidia (NASDAQ: NVDA). Following the news of new tariffs, in combination with intensifying competition in China, the company's